Eli Lilly and Company

LLY

1079.75 (0.11%) 1.15

Health Care

Pharmaceuticals

Eli Lilly and Company discovers develops and markets human pharmaceuticals in the United States Europe China Japan and internationally. The company offers Basaglar Humalog Humalog Mix 75/25 Humalog U-100 Humalog U-200 Humalog Mix 50/50 insulin lispro insulin lispro protamine insulin lispro mix 75/25 Humulin Humulin 70/30 Humulin N Humulin R and Humulin U-500 for diabetes; Jardiance Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products including Alimta Cyramza Erbitux Jaypirca Retevmo Tyvyt and Verzenio. In addition the company offers Olumiant for rheumatoid arthritis atopic dermatitis severe alopecia areata and COVID-19; Taltz for plaque psoriasis psoriatic arthritis ankylosing spondylitis and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder fibromyalgia and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd and Genentech Inc.; Biologics Inc. AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co. Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis Indiana.

Quality Checklist 6/8

5Y Shares Out Change < 0%

ROIC > 10%

Current Ratio > 1

Net Margin > 10%

Past Net Income CAGR > 0%

Est. EPS Growth > 5%

Debt/Equity < 1

Quick Ratio > 1

0.0%of Portfolio

My holdings

Day change:

Total change:

Cost basis:

Market cap: $966.79(B)

EV: $999.19(B)

Total Equity: $23.85(B)

Earnings date: Feb-06-2026

P/E: 52.67

Forward P/E: 45.69

P/FCF: 104.32

P/S: 16.32

P/B: 40.65

EPS: $20.5

EPS (fwd): $23.6

FCF/share: $10.3

Revenue/share: $66.2

Book value/share: $26.6

ROIC: 32.9%

ROA: 19.3%

ROE: 96.8%

Debt/Equity: 1.79

Current Ratio: 1.50

Gross margin: 83.0%

Operating margin: 45.1%

Net margin: 31.0%

Dividend/share: $5.8

Div. yield: 0.54%

All Valuation Overview Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools

LLY Valuation & Price Targets

Current Price

$1080

Favorite Valuation Methods

PEvaluation

N/A

Analyst targets

N/A

DCF (2-stage)

N/A

More Valuation Methods

DCF (simple)

N/A

DCF (exit mult.)

N/A

DDM

N/A

EPS growth

N/A

Revenue growth

N/A

Peter Lynch FV

N/A

Graham No.

N/A

PEvaluation

22% overvalued

Low

$631

Mid

$842

High

$1052

Current price

$1080

Fair P/E

Margin of safety

EPS

Market Model

Economic moat: Very wide

EPS Estimates

	Low	Avg	High	#
FY+1	22.3	23.6	25.4	28
FY+2	27.1	32.5	39.2	28
FY+3	35.2	40.1	46.1	23
FY+4	39.2	46.8	55.3	14
FY+5	41.4	52.8	62.2	14

Analyst Price Targets

6% undervalued

Low

$770

Mid

$1145

High

$1500

Current price

$1080

Analyst Recommendations

Strong Buy4

Buy18

Hold7

Sell0

Strong Sell1

2-stage DCF

First Stage Duration: 5 Years

Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh

Terminal Growth Rate
LowMidHigh

Discount Rate

Discounted Cash Flow

Forecast years: 5 Years

Terminal Growth Rate
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years

Exit FCF Multiple
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years

First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years

Starting EPS
EPS Growth Rate
LowMidHigh

Final P/E
LowMidHigh

Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years

Base Revenue
Revenue Growth Rate
LowMidHigh

Final Net Margin
LowMidHigh

Final P/E Ratio
LowMidHigh

Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact